Phase 3 ARANOTE Study of ADT + Darolutamide: Safety

Opinion
Video

Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and apalutamide reveal clinically relevant distinctions in their safety profiles, including the most common and challenging toxicities, incidence of grade 3 or higher adverse events, treatment discontinuations, and potential drug-drug interactions. He highlights key factors that influence treatment choice and disease management in patients with metastatic hormone-sensitive prostate cancer.

Video content above is prompted by the following:

  1. What about the safety data available for these regimens? What do you view as clinically relevant distinctions in their safety profiles?
    1. Most common/challenging toxicities
    2. Incidence of grade 3 or higher adverse events, discontinuations
    3. Drug-drug interactions
Recent Videos
Hope S. Rugo, MD, FASCO, is featured in this series.
Related Content